Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate ...
NOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to he...
Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U....
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintai...
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of...
